Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity. Issue 5 (20th May 2021)
- Record Type:
- Journal Article
- Title:
- Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity. Issue 5 (20th May 2021)
- Main Title:
- Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity
- Authors:
- Wang, Zining
Xu, Feifei
Hu, Jie
Zhang, Hongxia
Cui, Lei
Lu, Wenhua
He, Wenzhuo
Wang, Xiaojuan
Li, Mengyun
Zhang, Huanling
Xiong, Wenjing
Xie, Chunyuan
Liu, Yongxiang
Zhou, Penghui
Liu, Jinyun
Huang, Peng
Qin, Xiaofeng Frank
Xia, Xiaojun - Abstract:
- Abstract : Background: Dendritic cells (DCs) play a critical role in antitumor immunity, but the therapeutic efficacy of DC-mediated cancer vaccine remains low, partly due to unsustainable DC function in tumor antigen presentation. Thus, identifying drugs that could enhance DC-based antitumor immunity and uncovering the underlying mechanism may provide new therapeutic options for cancer immunotherapy. Methods: In vitro antigen presentation assay was used for DC-modulating drug screening. The function of DC and T cells was measured by flow cytometry, ELISA, or qPCR. B16, MC38, CT26 tumor models and C57BL/6, Balb/c, nude, and Batf3 −/− mice were used to analyze the in vivo therapy efficacy and impact on tumor immune microenvironment by clotrimazole treatment. Results: By screening a group of small molecule inhibitors and the US Food and Drug Administration (FDA)-approved drugs, we identified that clotrimazole, an antifungal drug, could promote DC-mediated antigen presentation and enhance T cell response. Mechanistically, clotrimazole acted on hexokinase 2 to regulate lactate metabolic production and enhanced the lysosome pathway and Chop expression in DCs subsequently induced DC maturation and T cell activation. Importantly, in vivo clotrimazole administration induced intratumor immune infiltration and inhibited tumor growth depending on both DCs and CD8+ T cells and potentiated the antitumor efficacy of anti-PD1 antibody. Conclusions: Our findings showed that clotrimazoleAbstract : Background: Dendritic cells (DCs) play a critical role in antitumor immunity, but the therapeutic efficacy of DC-mediated cancer vaccine remains low, partly due to unsustainable DC function in tumor antigen presentation. Thus, identifying drugs that could enhance DC-based antitumor immunity and uncovering the underlying mechanism may provide new therapeutic options for cancer immunotherapy. Methods: In vitro antigen presentation assay was used for DC-modulating drug screening. The function of DC and T cells was measured by flow cytometry, ELISA, or qPCR. B16, MC38, CT26 tumor models and C57BL/6, Balb/c, nude, and Batf3 −/− mice were used to analyze the in vivo therapy efficacy and impact on tumor immune microenvironment by clotrimazole treatment. Results: By screening a group of small molecule inhibitors and the US Food and Drug Administration (FDA)-approved drugs, we identified that clotrimazole, an antifungal drug, could promote DC-mediated antigen presentation and enhance T cell response. Mechanistically, clotrimazole acted on hexokinase 2 to regulate lactate metabolic production and enhanced the lysosome pathway and Chop expression in DCs subsequently induced DC maturation and T cell activation. Importantly, in vivo clotrimazole administration induced intratumor immune infiltration and inhibited tumor growth depending on both DCs and CD8+ T cells and potentiated the antitumor efficacy of anti-PD1 antibody. Conclusions: Our findings showed that clotrimazole could trigger DC activation via the lactate-lysosome axis to promote antigen cross-presentation and could be used as a potential combination therapy approach to improving the therapeutic efficacy of anti-PD1 immunotherapy. … (more)
- Is Part Of:
- Journal for immunotherapy of cancer. Volume 9:Issue 5(2021)
- Journal:
- Journal for immunotherapy of cancer
- Issue:
- Volume 9:Issue 5(2021)
- Issue Display:
- Volume 9, Issue 5 (2021)
- Year:
- 2021
- Volume:
- 9
- Issue:
- 5
- Issue Sort Value:
- 2021-0009-0005-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-05-20
- Subjects:
- dendritic cells -- immunotherapy
Cancer -- Immunotherapy -- Periodicals
Cancer -- Immunological aspects -- Periodicals
Tumors -- Immunological aspects -- Periodicals
Immunotherapy -- Periodicals
616.99406105 - Journal URLs:
- http://www.immunotherapyofcancer.org ↗
https://jitc.bmj.com/ ↗
http://link.springer.com/ ↗ - DOI:
- 10.1136/jitc-2020-002155 ↗
- Languages:
- English
- ISSNs:
- 2051-1426
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 16849.xml